Brand | bilypsa |
Composition | saroglitazar |
Brand Name | Bilypsa |
Treatment | diabteis |
Manufacturer | Zydus bionext |
Prescription/Non prescription | Non prescription |
Dose | 4 mg |
Packaging Size | 45 tab |
Packaging Type | bottel |
SaroglitazarSAROGLITAZAR is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetic patients, which is not controlled by statins (lipid-lowering agents) alone. SAROGLITAZAR has both lipid and glucose-lowering effects in a single molecule; thereby, helps lower blood triglycerides and blood glucose levels. Diabetic dyslipidaemia is characterised by increased triglyceride levels, low-density lipoproteins (LDL) and decreased high-density lipoprotein (HDL) levels. This condition is common in people with type-2 diabetes mellitus.
Additional Information:
- Item Code: 3004997
- Production Capacity: 109877
- Delivery Time: 1 day
- Packaging Details: SAROGLITAZAR is an insulin sensitiser used to treat diabetic dyslipidaemia/hypertriglyceridemia in type-2 diabetic patients, which is not controlled by statins (lipid-lowering agents) alone. SAROGLITAZAR has both lipid and glucose-lowering effects in a single molecule; thereby, helps lower blood triglycerides and blood glucose levels. Diabetic dyslipidaemia is characterised by increased triglyceride levels, low-density lipoproteins (LDL) and decreased high-density lipoprotein (HDL) levels. This condition is common in people with type-2 diabetes mellitus.